GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » EBIT

Circio Holding ASA (OSL:CRNA) EBIT : kr11.50 Mil (TTM As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA EBIT?

Circio Holding ASA's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was kr48.25 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was kr11.50 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Circio Holding ASA's annualized ROC % for the quarter that ended in Jun. 2024 was -54.84%. Circio Holding ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 104,317.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Circio Holding ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 16.39%.


Circio Holding ASA EBIT Historical Data

The historical data trend for Circio Holding ASA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA EBIT Chart

Circio Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -146.83 -104.05 -95.99 -490.33 -107.18

Circio Holding ASA Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.66 -432.67 -70.43 -36.75 48.25

Competitive Comparison of Circio Holding ASA's EBIT

For the Biotechnology subindustry, Circio Holding ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Circio Holding ASA's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Circio Holding ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Circio Holding ASA's EV-to-EBIT falls into.



Circio Holding ASA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr11.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA  (OSL:CRNA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Circio Holding ASA's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-45.616 * ( 1 - 0% )/( (121.034 + 45.323)/ 2 )
=-45.616/83.1785
=-54.84 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Circio Holding ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=96.494/( ( (0 + max(-12.274, 0)) + (0.185 + max(-11.197, 0)) )/ 2 )
=96.494/( ( 0 + 0.185 )/ 2 )
=96.494/0.0925
=104,317.84 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.108 + 0 + 1.436) - (3.45 + 0 + 10.368)
=-12.274

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.454 + 0 + 8.8817841970013E-16) - (5.522 + 0 + 10.129)
=-11.197

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Circio Holding ASA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=11.499/70.149
=16.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA EBIT Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Circio Holding ASA Business Description

Traded in Other Exchanges
Address
Saint Olavs plass, Pb. 6887, Oslo, NOR, 0130
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.

Circio Holding ASA Headlines

No Headlines